… to investigate individual DOAC safety and effectiveness against … safety of rivaroxaban
versus warfarin for the treatment of VTE in morbidly obese patients with a weight >120 kg or BMI >…

… of 40 kg/m 2 or higher who newly initiated apixaban, rivaroxaban, or … obese patients had
a VTE recurrence rate at 12 months that was not significantly different from those patients who …

… All patients enrolled in the COMPASS trial received the same dose of rivaroxaban despite
a broad range of BMI and body weights (5). Obesity has been shown to influence the …

… and 0.63, respectively) in rivaroxaban-treated patients. Major bleeding events were
numerically lower in rivaroxaban-treated patients across all body weight and BMI categories [18]. …

… The most frequently prescribed drug in this group was rivaroxaban (40%). … patients with
morbid obesity included in the ROCKET trial. In our study, none of the morbidly obese patients …

… obese patients. We sought to examine the efficacy and safety of the DOACs, apixaban,
dabigatran, and rivaroxaban… bleeding events in patients with either a body-mass index (BMI) over …

… of NVAF patients with obesity and polypharmacy in the US. We hypothesized that
rivaroxaban would be an effective and safe treatment option for NVAF patients with obesity and …

… safety of DOACs in obese patients are limited. We reviewed the available data on the use of
DOACs in obese patients … the effects of obesity on the pharmacokinetics of rivaroxaban. The …

… validate rivaroxaban use in extreme BW and BMI patients. In this article, we report a morbidly
obese patient with recurrent upper extremity DVT (UEDVT) while taking rivaroxaban for …

… obese individuals remains uncertain. We present the case of an extremely obese patient (BMI
>… (DVT) successfully treated with rivaroxaban with demonstrable therapeutic anti-Xa levels …